• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

质子泵抑制剂治疗和白蛋白比抗生素选择更能预测复发性艰难梭菌结肠炎。

PPI therapy and albumin are better predictors of recurrent Clostridium difficile colitis than choice of antibiotics.

机构信息

Division of Colon and Rectal Surgery, Department of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA 17033, USA.

出版信息

J Gastrointest Surg. 2012 Dec;16(12):2267-73. doi: 10.1007/s11605-012-2037-9. Epub 2012 Sep 25.

DOI:10.1007/s11605-012-2037-9
PMID:23007285
Abstract

BACKGROUND

Recurrent Clostridium difficile colitis (RCDC) is common, but data regarding recurrence rates and predisposing factors are sparse.

METHODS

A retrospective case-control study was performed, identifying all inpatients and outpatients ≥18 years of age with C. difficile colitis (CDC) confirmed by a positive stool sample collected at our institution from January 2008 to August 2011. Factors associated with RCDC, the number of RCDC episodes, and the need for admission for RCDC were sought.

RESULTS

A total of 739 patients (male, 47 %) were studied, of whom 527 (71 %) received inpatient treatment for their index episode of CDC. There was no difference (p = 0.53) between RCDC rates for inpatients (17.6 %) and outpatients (19.8 %). While severity score and albumin were associated with RCDC in our population, use of proton pump inhibitors (PPIs) correlated with decreased RCDC (p = 0.006) and decreased need for admission (p = 0.005). The addition of vancomycin to metronidazole therapy did not lower RCDC rates (p = 0.52) or decrease the need for admission (p = 0.78).

CONCLUSIONS

Hypoalbuminemia strongly correlated with higher recurrence rates, while PPI therapy actually reduced RCDC, representing previously underappreciated potential therapeutic targets for lowering CDC recurrence. The addition of vancomycin to metronidazole did not improve RCDC rates.

摘要

背景

复发性艰难梭菌结肠炎(RCDC)很常见,但关于复发率和易患因素的数据却很少。

方法

我们进行了一项回顾性病例对照研究,确定了 2008 年 1 月至 2011 年 8 月在我院采集的阳性粪便样本确诊为艰难梭菌结肠炎(CDC)的所有≥18 岁的住院和门诊患者。寻找与 RCDC 相关的因素、RCDC 发作次数以及 RCDC 住院的必要性。

结果

共研究了 739 例患者(男性占 47%),其中 527 例(71%)因 CDC 指数发作接受住院治疗。住院患者(17.6%)和门诊患者(19.8%)的 RCDC 发生率没有差异(p=0.53)。虽然严重程度评分和白蛋白与本人群中的 RCDC 相关,但质子泵抑制剂(PPIs)的使用与 RCDC 减少相关(p=0.006),并降低了住院的必要性(p=0.005)。万古霉素联合甲硝唑治疗并未降低 RCDC 发生率(p=0.52)或减少住院的必要性(p=0.78)。

结论

低白蛋白血症与较高的复发率密切相关,而 PPI 治疗实际上降低了 RCDC,这代表了以前被低估的降低 CDC 复发的潜在治疗靶点。万古霉素联合甲硝唑治疗并未改善 RCDC 发生率。

相似文献

1
PPI therapy and albumin are better predictors of recurrent Clostridium difficile colitis than choice of antibiotics.质子泵抑制剂治疗和白蛋白比抗生素选择更能预测复发性艰难梭菌结肠炎。
J Gastrointest Surg. 2012 Dec;16(12):2267-73. doi: 10.1007/s11605-012-2037-9. Epub 2012 Sep 25.
2
Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.日本艰难梭菌(梭状芽孢杆菌)感染复发的特征和危险因素:使用大型基于医院的行政数据集进行的全国真实世界分析。
J Infect Chemother. 2019 Aug;25(8):615-620. doi: 10.1016/j.jiac.2019.03.011. Epub 2019 Apr 12.
3
Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea.质子泵抑制剂作为艰难梭菌相关性腹泻复发的危险因素。
World J Gastroenterol. 2010 Jul 28;16(28):3573-7. doi: 10.3748/wjg.v16.i28.3573.
4
Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis.
Am J Health Syst Pharm. 2007 Nov 15;64(22):2359-63. doi: 10.2146/ajhp060629.
5
Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.质子泵抑制剂与住院患者中复发性艰难梭菌感染的风险。
Am J Gastroenterol. 2013 Nov;108(11):1794-801. doi: 10.1038/ajg.2013.333. Epub 2013 Sep 24.
6
Predictors of Clostridioides difficile recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings.预测门诊、急性和长期护理环境中全国退伍军人队列中艰难梭菌复发的因素。
Am J Health Syst Pharm. 2019 Apr 17;76(9):581-590. doi: 10.1093/ajhp/zxz032.
7
Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score.质子泵抑制剂的使用与复发性艰难梭菌相关性疾病:基于倾向评分匹配的病例对照分析。
J Clin Gastroenterol. 2012 May-Jun;46(5):397-400. doi: 10.1097/MCG.0b013e3182431d78.
8
Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature.利福昔明和替加环素成功治疗复发性难治性艰难梭菌结肠炎:一例病例报告及文献复习
Scand J Infect Dis. 2012 Mar;44(3):228-30. doi: 10.3109/00365548.2011.616224. Epub 2011 Nov 13.
9
Outcome of Clostridioides difficile infections treated in a Swiss tertiary care hospital: an observational study.瑞士一家三级保健医院治疗艰难梭菌感染的结果:一项观察性研究。
Swiss Med Wkly. 2020 Jan 15;150:w20173. doi: 10.4414/smw.2020.20173.
10
Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection.连续质子泵抑制剂治疗与复发性艰难梭菌感染的相关风险。
JAMA Intern Med. 2015 May;175(5):784-91. doi: 10.1001/jamainternmed.2015.42.

引用本文的文献

1
Clinical Presentations, Predictive Factors, and Outcomes of Clostridioides difficile Infection among COVID-19 Hospitalized Patients—A Single Center Experience from the COVID Hospital of the University Clinical Center of Vojvodina, Serbia.COVID-19 住院患者中艰难梭菌感染的临床特征、预测因素和结局——来自塞尔维亚伏伊伏丁那大学临床中心 COVID 医院的单中心经验。
Medicina (Kaunas). 2022 Sep 12;58(9):1262. doi: 10.3390/medicina58091262.
2
Infection: An Epidemiology Update.感染:流行病学最新进展
Clin Colon Rectal Surg. 2020 Mar;33(2):49-57. doi: 10.1055/s-0040-1701229. Epub 2020 Feb 25.
3
Comorbid status and the faecal microbial transplantation failure in treatment of recurrent Clostridioides difficile infection - pilot prospective observational cohort study.

本文引用的文献

1
Fidaxomicin for the treatment of Clostridium difficile infections. fidaxomicin 治疗艰难梭菌感染。
Ann Pharmacother. 2012 Feb;46(2):219-28. doi: 10.1345/aph.1Q481. Epub 2012 Feb 7.
2
Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score.质子泵抑制剂的使用与复发性艰难梭菌相关性疾病:基于倾向评分匹配的病例对照分析。
J Clin Gastroenterol. 2012 May-Jun;46(5):397-400. doi: 10.1097/MCG.0b013e3182431d78.
3
High prevalence of Clostridium difficile colonization among nursing home residents in Hesse, Germany.
合并症状况与粪菌移植治疗复发性艰难梭菌感染失败的关系:一项前瞻性观察队列研究
BMC Infect Dis. 2020 Jan 16;20(1):52. doi: 10.1186/s12879-020-4773-x.
4
Combined administration of antibiotics increases the incidence of antibiotic-associated diarrhea in critically ill patients.联合使用抗生素会增加重症患者抗生素相关性腹泻的发生率。
Infect Drug Resist. 2019 May 1;12:1047-1054. doi: 10.2147/IDR.S194715. eCollection 2019.
5
Factors related to antibiotic-associated diarrhea in patients in the intensive care unit receiving antifungals: a single-center retrospective study.接受抗真菌药物治疗的重症监护病房患者中与抗生素相关性腹泻相关的因素:一项单中心回顾性研究。
J Int Med Res. 2019 May;47(5):2067-2076. doi: 10.1177/0300060519836305. Epub 2019 Mar 21.
6
2019 update of the WSES guidelines for management of () infection in surgical patients.2019 年 WSES 外科患者()感染管理指南更新。
World J Emerg Surg. 2019 Feb 28;14:8. doi: 10.1186/s13017-019-0228-3. eCollection 2019.
7
Hypoalbuminemia as predictor of recurrence of Clostridium difficile infection.低白蛋白血症作为艰难梭菌感染复发的预测指标。
Wien Klin Wochenschr. 2019 Feb;131(3-4):68-74. doi: 10.1007/s00508-018-1432-y. Epub 2019 Jan 7.
8
Enzyme Inhibitor Antibiotics and Antibiotic-Associated Diarrhea in Critically Ill Patients.危重症患者的酶抑制剂抗生素与抗生素相关性腹泻。
Med Sci Monit. 2018 Dec 4;24:8781-8788. doi: 10.12659/MSM.913739.
9
Risk Factors for Antibiotic-Associated Diarrhea in Critically Ill Patients.危重症患者抗生素相关性腹泻的危险因素。
Med Sci Monit. 2018 Jul 18;24:5000-5007. doi: 10.12659/MSM.911308.
10
Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis.质子泵抑制剂治疗与艰难梭菌感染风险:系统评价和荟萃分析。
World J Gastroenterol. 2017 Sep 21;23(35):6500-6515. doi: 10.3748/wjg.v23.i35.6500.
德国黑森州养老院居民中艰难梭菌定植的高流行率。
PLoS One. 2012;7(1):e30183. doi: 10.1371/journal.pone.0030183. Epub 2012 Jan 11.
4
Fidaxomicin versus vancomycin for Clostridium difficile infection. fidaxomicin 与万古霉素治疗艰难梭菌感染。
N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.
5
The diverse sporulation characteristics of Clostridium difficile clinical isolates are not associated with type.艰难梭菌临床分离株的不同孢子形成特征与类型无关。
Anaerobe. 2010 Dec;16(6):618-22. doi: 10.1016/j.anaerobe.2010.10.001. Epub 2010 Oct 13.
6
The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings.艰难梭菌感染在住院和门诊环境中的发病率和严重程度不断增加。
Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):409-16. doi: 10.1586/egh.10.48.
7
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).艰难梭菌感染临床实践指南:美国医疗保健流行病学学会(SHEA)和美国传染病学会(IDSA)2010 年更新版。
Infect Control Hosp Epidemiol. 2010 May;31(5):431-55. doi: 10.1086/651706.
8
Clostridium difficile infection: new developments in epidemiology and pathogenesis.艰难梭菌感染:流行病学与发病机制的新进展
Nat Rev Microbiol. 2009 Jul;7(7):526-36. doi: 10.1038/nrmicro2164.
9
Clostridium difficile and fluoroquinolones: is there a link?艰难梭菌与氟喹诺酮类药物:存在关联吗?
Int J Antimicrob Agents. 2009 Mar;33 Suppl 1:S29-32. doi: 10.1016/S0924-8579(09)70013-5.
10
A case-control study of community-associated Clostridium difficile infection.一项关于社区相关性艰难梭菌感染的病例对照研究。
J Antimicrob Chemother. 2008 Aug;62(2):388-96. doi: 10.1093/jac/dkn163. Epub 2008 Apr 22.